Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: The ACT-RAY study

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 803-809

  Dougados, Maxime ^a   Kissel, Karsten ^b   Conaghan, Philip G ^c   Mola, Emilio Martin ^d   Schett, Georg ^e   Gerli, Roberto ^f   Hansen, Michael Sejer ^g   Amital, Howard ^h   Xavier, Ricardo M ⁱ   Troum, Orrin ^j   Bernasconi, Corrado ^k   Huizinga, T W J ^l  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Roche Products Pty Ltd   (Australia)

^c Chapel Allerton Hospital   (United Kingdom)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITY OF PERUGIA   (Italy)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLOROQUINE; CORTICOSTEROID; DRUG ANTIBODY; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE EROSION; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DAS28; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SKIN NECROSIS; TENDON RUPTURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

DMARDS (BIOLOGIC); METHOTREXATE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84897971056     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204761     Document Type: Article

References (26)

1. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
3. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
4. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoidarthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
5. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9. (Pubitemid 41206242)
6. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20. (Pubitemid 19104569)
7. Schnabel A, Reinhold-Keller E, Willmann V, et al. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994;14:33-8. (Pubitemid 24189748)
8. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
9. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;65:1413-8.
10. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
11. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-97. (Pubitemid 351392039)
12. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
13. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
14. Kremer J, Furst D, Burgos-Vargas R, et al. LITHE: tocilizumab (TCZ) inhibits radiographic progression, maintains clinical efficacy in rheumatoid arthritis (RA) patients (PTS) at 3 years [abstract]. Ann Rheum Dis 2011;70(Suppl3):467.
15. Khraishi M, Alten R, Gomez-Reino JJ, et al. Long-term efficacy of tocilizumab (TCZ) in patients (pts) with rheumatoid arthritis (RA) treated up to 3.7 years [abstract]. Arthritis Rheum 2010;62:S7609.
16. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
17. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82. (Pubitemid 40193607)
18. Aletaha D, Strand V, Smolen JS, et al. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43. (Pubitemid 351183315)
19. Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/ EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1815-21.
20. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. (Pubitemid 38530193)
21. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6. (Pubitemid 46477484)
22. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-52.
23. Stubenrauch K, Wessels U, Birnboeck H, et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
24. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013;65:362-71.
25. Bykerk VP, Ostor AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71: 1950-4.
26. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.